STOCK TITAN

Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Curis, Inc. (NASDAQ: CRIS) has announced the rescheduling of its fourth quarter business update and investor conference call from March 9, 2023, to March 13, 2023. The update will be released at 8:00 a.m. ET, followed by the conference call at 8:30 a.m. ET. To access the call, investors can dial (888)-346-6389 or (412)-317-5252 for international calls, or join via the Curis website. The company focuses on innovative cancer therapeutics, collaborating with partners like Aurigene and Genentech, currently testing drug candidates in various trials, including a Phase 1/2 trial for its IRAK4 inhibitor, emavusertib.

Positive
  • Curis is actively engaged in developing innovative cancer therapies.
  • The company has collaborations with Aurigene and Genentech to advance its drug candidates.
Negative
  • The FDA has placed a partial clinical hold on the TakeAim Leukemia trial, limiting new patient enrollment.

LEXINGTON, Mass., March 8, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it is rescheduling its fourth quarter business update and quarterly investor conference call previously scheduled for Thursday, March 9, 2023 at 4:30 p.m. ET to Monday, March 13, 2023 at 8:30 a.m. ET.  The business update will be released at 8:00 a.m. ET on March 13, followed by an investor conference call hosted by management at 8:30 a.m. ET.

To access the live conference call, please dial (888)-346-6389 from the United States or (412)-317-5252 from other locations, shortly before 8:30 a.m. ET. The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section. A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.

About Curis, Inc.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, emavusertib (CA-4948). Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma trial in patients with hematologic malignancies, such as non-Hodgkin's lymphoma and other B cell malignancies, both as a monotherapy and in combination with BTK inhibitor ibrutinib, and the Phase 1/2 TakeAim Leukemia trial in patients with acute myeloid leukemia and myelodysplastic syndrome, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. The FDA has placed a partial clinical hold on the TakeAim Leukemia trial during which no new patients will be enrolled in the monotherapy expansion phase (Phase 2a) or the combination phase (Phase 1b) of emavusertib with azacitidine or venetoclax. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1 trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-reschedules-fourth-quarter-2022-business-update-and-conference-call-301766395.html

SOURCE Curis, Inc.

FAQ

When is the rescheduled conference call for Curis, Inc.?

The conference call is rescheduled for March 13, 2023, at 8:30 a.m. ET.

What will be discussed in the Curis, Inc. business update?

The business update will include fourth quarter results and company developments.

How can investors access the Curis, Inc. conference call?

Investors can access the call at (888)-346-6389 from the U.S. or (412)-317-5252 internationally.

What is the status of Curis's clinical trials?

Curis is conducting trials for emavusertib but faces a partial clinical hold on the TakeAim Leukemia trial.

What is Curis, Inc.'s focus in biotechnology?

Curis focuses on developing innovative therapeutics for cancer treatment.

Curis Inc

NASDAQ:CRIS

CRIS Rankings

CRIS Latest News

CRIS Stock Data

25.82M
7.90M
6.78%
24.37%
2.28%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
LEXINGTON